Cancer risk among parous women following assisted reproductive technology

Human Reproduction

Volumn 30, Issue 8, 2015, Pages 1952-1963

  Reigstad, M M ^a,b   Larsen, I K ^b   Myklebust, T A ^b   Robsahm, T E ^b   Oldereid, N B ^a   Omland, A K ^a   Vangen, S ^a   Brinton, L A ^c   Storeng, R ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

assisted reproductive technology; brain tumor; cancer; IVF; neoplasm of the central nervous system

Indexed keywords

ADULT; ARTICLE; BRAIN CANCER; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; MELANOMA; NORWAY; PARITY; RISK ASSESSMENT; THYROID CANCER; UTERINE CERVIX CANCER; UTERUS CANCER; ADVERSE EFFECTS; INFERTILITY; MIDDLE AGED; NEOPLASMS; PREGNANCY; REGISTER; RETROSPECTIVE STUDY; RISK; YOUNG ADULT;

ADULT; FEMALE; HUMANS; INFERTILITY; MIDDLE AGED; NEOPLASMS; NORWAY; PARITY; PREGNANCY; REGISTRIES; REPRODUCTIVE TECHNIQUES, ASSISTED; RETROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; YOUNG ADULT;

EID: 84939641397     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dev124     Document Type: Article

References (57)

1. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-1254.
2. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-1568.
3. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005;193:668-674.
4. Andersen AN, Carlsen E, Loft A. Trends in the use of intracytoplasmatic sperm injection marked variability between countries. Hum Reprod Update 2008;14:593-604.
5. Andersen L, Friis S, Hallas J, Ravn P, Gaist D. Hormone replacement therapy and risk of glioma: a nationwide nested case-control study. Cancer Epidemiol 2013;37:876-880.
6. Andersen L, Friis S, Hallas J, Ravn P, Kristensen BW, Gaist D. Hormonal contraceptive use and risk of glioma among younger women a nationwide case-control study. Br J Clin Pharmacol 2015;79:677-684.
7. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-284.
8. Benson VS, Pirie K, Green J, Bull D, Casabonne D, Reeves GK, Beral V, Million Women Study C. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study. Int J Cancer 2010;127:1692-1698.
9. Bjornholt SM, Kjaer SK, Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod 2015;30:222-231.
10. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 2004;103:1194-1203.
11. Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013;99:1189-1196.
12. Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Ruggieri D, Trabert B, Lamb EJ. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2014;23:584-593.
13. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009;169:365-375.
14. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: application to dementia. Stat Med 1998;17:1973-1988.
15. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-2213.
16. Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control 2008a;19:759-765.
17. Hannibal CG, Jensen A, Sharif H, Kjaer SK. Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study. Hum Reprod 2008b;23:451-456.
18. Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG, Black PM, Inskip PD. Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 2005;114:797-805.
19. Horn J, Opdahl S, Engstrom MJ, Romundstad PR, Tretli S, Haugen OA, Bofin AM, Vatten LJ, Asvold BO. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. Cancer Causes Control 2014;25:881-889.
20. Jensen A, Sharif H, Svare EI, Frederiksen K, Kjaer SK. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev 2007;16:1400-1407.
21. Kallen B, Finnstrom O, Lindam A, Nilsson E, Nygren KG, Olausson PO. Malignancies among women who gave birth after in vitro fertilization. Hum Reprod 2011;26:253-258.
22. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988a;57:205-212.
23. Key TJ, Pike MC. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988b;24:29-43.
24. Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009;20:358-364.
25. La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L et al. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999;10:157-166.
26. Larsen I, Smastuen M, Johannesen T, Langmark F, Parkin D, Bray F, Moller B. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-1231.
27. Lerner-Geva L, Geva E, Lessing JB, Chetrit A, Modan B, Amit A. The possible association between in vitro fertilization treatments and cancer development. Int J Gynecol Cancer 2003;13:23-27.
28. Louis JF, Thoma ME, Sorensen DN, McLain AC, King RB, Sundaram R, Keiding N, Buck Louis GM. The prevalence of couple infertility in the United States from a male perspective: evidence from a nationally representative sample. Andrology 2013;1:741-748.
29. Moodley M, Moodley J, Chetty R, Herrington CS. The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: a review. Int J Gynecol Cancer 2003;13:103-110.
30. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224.
31. Nichols HB, Trentham-Dietz A, Hampton JM, Newcomb PA. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev 2005;14:1212-1218.
32. Orgeas CC, Sanner K, Hall P, Conner P, Holte J, Nilsson SJ, Sundfeldt K, Persson I, Chia KS, Wedren S et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol 2009;200:72 e71-77.
33. Pazaitou-Panayiotou K, Toulis KA, Mandanas S, Tarlatzis BC. Thyroid cancer after in vitro fertilization: a retrospective, non-consecutive case-series analysis. Gynecol Endocrinol 2014;30:569-572.
34. Practice Committees of the American Society for Reproductive Medicine. Intracytoplasmic sperm injection (ICSI) for non-male factor infertility: a committee opinion. Fertil Steril 2012;98:1395-1399.
35. Reigstad MM, Larsen IK, Myklebust TÅ, Robsahm TE, Oldereid NB, Omland AK, Vangen S, Brinton LA, Storeng R. Risk of breast cancer following fertility treatment-A registry based cohort study of parous women in Norway. Int J Cancer 2015;136:1140-1148.
36. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994;140:585-597.
37. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776.
38. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995;5:123-127.
39. Rossing MA, Voigt LF, Wicklund KG, Daling JR. Reproductive factors and risk of papillary thyroid cancer in women. Am J Epidemiol 2000;151:765-772.
40. Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 2004;160:1070-1078.
41. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE. Cervical cancer prevention: new tools and old barriers. Cancer 2010;116:2531-2542.
42. Schoenfeld D. Partial residuals for the proportional hazards regression-model. Biometrika 1982;69:239-241.
43. Shy H, Malaiyandi L, Timiras PS. Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells. Int J Dev Neurosci 2000;18:289-297.
44. Silva Idos S, Wark PA, McCormack VA, Mayer D, Overton C, Little V, Nieto J, Hardiman P, Davies M, MacLean AB. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer 2009;100:1824-1831.
45. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, Psaltopoulou T, Skalkidou A, Petridou ET. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer - a systematic review and meta-analysis. Hum Reprod Update 2013;19:105-123.
46. Slama R, Hansen OK, Ducot B, Bohet A, Sorensen D, Giorgis Allemand L, Eijkemans MJ, Rosetta L, Thalabard JC, Keiding N et al. Estimation of the frequency of involuntary infertility on a nation-wide basis. Hum Reprod 2012;27:1489-1498.
47. Spaan M, van den Belt-Dusebout AW, Schaapveld M, Mooij TM, Burger CW, van Leeuwen FE, OMEGA-project group. Melanoma risk after ovarian stimulation for in vitro fertilization. Hum Reprod 2015;30:1216-1228.
48. Stewart LM, Holman CD, Finn JC, Preen DB, Hart R. Association between in-vitro fertilization, birth and melanoma. Melanoma Res 2013;23:489-495.
49. Sunderam S, Kissin DM, Crawford S, Anderson JE, Folger SG, Jamieson DJ, Barfield WD, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. Assisted reproductive technology surveillance - United States, 2010. MMWR Surveill Summ 2013;62:1-24.
50. Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Brinton LA. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertil Steril 2013;100:1660-1666.
51. van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 2011;26:3456-3465.
52. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-1590.
53. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-1220.
54. Wigertz A, Lonn S, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ et al. Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008;17:2663-2670.
55. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002;4:278-299.
56. Wright VC, Schieve LA, Reynolds MA, Jeng G, Kissin D. Assisted reproductive technology surveillance - United States, 2001. MMWR Surveill Summ 2004;53:1-20.
57. Yli-Kuha AN, Gissler M, Klemetti R, Luoto R, Hemminki E. Cancer morbidity in a cohort of 9175 Finnish women treated for infertility. Hum Reprod 2012;27:1149-1155.